These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 15607123

  • 1. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD.
    Hanania NA, Kalberg C, Yates J, Emmett A, Horstman D, Knobil K.
    Pulm Pharmacol Ther; 2005; 18(1):19-22. PubMed ID: 15607123
    [Abstract] [Full Text] [Related]

  • 2. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
    Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T.
    Am J Respir Crit Care Med; 2002 Oct 15; 166(8):1084-91. PubMed ID: 12379552
    [Abstract] [Full Text] [Related]

  • 4. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug 15; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 5. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C, Testi R, Polese G, Tosatto R, Rossi A.
    Pulm Pharmacol Ther; 2005 Aug 15; 18(2):103-8. PubMed ID: 15649852
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
    Make B, Hanania NA, ZuWallack R, Kalberg C, Emmett A, Brown CP, Knobil K.
    Clin Ther; 2005 May 15; 27(5):531-42. PubMed ID: 15978302
    [Abstract] [Full Text] [Related]

  • 7. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr 15; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 8. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T.
    Ther Adv Respir Dis; 2009 Aug 15; 3(4):1-11. PubMed ID: 19734176
    [Abstract] [Full Text] [Related]

  • 9. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED, van Dyk M, Sagriotis A.
    Pulm Pharmacol Ther; 2008 Aug 15; 21(1):20-5. PubMed ID: 17118684
    [Abstract] [Full Text] [Related]

  • 10. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
    Cazzola M, Andò F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, D'Amato M.
    Pulm Pharmacol Ther; 2007 Aug 15; 20(5):556-61. PubMed ID: 16914336
    [Abstract] [Full Text] [Related]

  • 11. Combined salmeterol and fluticasone for COPD.
    Vassiliou V.
    Lancet; 2003 May 10; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, Banerji D.
    Lancet Respir Med; 2013 Mar 10; 1(1):51-60. PubMed ID: 24321804
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, Prillaman B, Shah T.
    Ann Allergy Asthma Immunol; 1999 Mar 10; 82(3):257-65. PubMed ID: 10094216
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.
    Respir Med; 2012 Jan 10; 106(1):91-101. PubMed ID: 22040533
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr 10; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 20. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB, Tillie-Leblond I, Attali V, Bavelele Z, Lagrange O.
    Respir Med; 2011 Feb 10; 105(2):250-8. PubMed ID: 20702076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.